louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT02456181: Investigation of Instructional Approaches to Elementary Math
Official title: Investigation of the Efficacy of the JUMP Program of Mathematics Instruction
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Student Math Achievement
Lead sponsor: The Hospital for Sick Children
Sponsor class: OTHER
First posted: 2015-05-28
Enrollment: 1156
Sex: ALL
Minimum age (years): 6
Maximum age (years): 13
Standard ages: CHILD
Accepts healthy volunteers: yes
Allocation: NA
Intervention model: SINGLE_GROUP

Brief summary: The overall aim of the proposed project is to test the efficacy of a relatively new, well-developed math program on the math achievement of elementary school students in mainstream classes in urban schools. Use of this program is increasing in Canada and the United Kingdom. Preliminary findings derived from uncontrolled trials and our own pilot, randomized controlled trial suggest it may yield meaningful gains in math achievement for both at-risk and achieving students, as indexed by their performance on national exams, in national math competitions, as well as on standardized measures of math achievement. However, the program has yet to be rigorously evaluated to determine its relative efficacy compared to the math programs typically used by school boards. The program provision of grade-specific teacher's guides and student workbooks (for grades 1 to 8), and minimal teacher training, points to its potential utility for full-scale implementation, should its efficacy be confirmed.


Eligibility criteria: Inclusion Criteria:

* The students must: have sufficient command of English to understand their teacher's instructions (as judged by their teacher, ELL students will be included provided they meet this criterion). They must have a signed parental consent form and also assent to participate in the study.

Exclusion Criteria:

* The students must have no uncorrected sensory, neurological, or physical impairments that would preclude the use of manipulatives, perceiving written math materials and figures, or hearing the teacher's instructions.

Primary outcomes:
measure: The change scores on the Math Fluency, Calculation, and Applied Problems sub scales from a standardized battery (WJ-III) and on a curriculum based math measure, as well as on the results from a regional math assessment test.
timeFrame: Fall and Spring of School Years 1 and 2 Years
Secondary outcomes:
Other outcomes:
Locations:
city: Toronto
country: Canada
facility: SickKids
state: Ontario
Study officials:
affiliation: The Hospital for Sick Children
name: Tracy Solomon, PhD
role: STUDY_DIRECTOR
References:
citation: Solomon T, Dupuis A, O'Hara A, Hockenberry MN, Lam J, Goco G, Ferguson B, Tannock R. A cluster-randomized controlled trial of the effectiveness of the JUMP Math program of math instruction for improving elementary math achievement. PLoS One. 2019 Oct 30;14(10):e0223049. doi: 10.1371/journal.pone.0223049. eCollection 2019.
Clinical trial NCT06288581: U Shaped Toothbrush in Removing Plaque in Children
Official title: Evaluating the Effectiveness of a U-shaped Toothbrush in Removing Plaque In Pre-school Children
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Dental Plaque
Keywords: U shaped toothbrush
Traditional toothbrush
Plaque removal
Oral hygiene
Pre-schooled children
Lead sponsor: Damascus University
Sponsor class: OTHER
First posted: 2024-03-01
Enrollment: 30
Sex: ALL
Minimum age (years): 4
Maximum age (years): 5
Standard ages: CHILD
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: The aim of this study is to evaluate the effectiveness of a U-shaped toothbrush in removing plaque in preschool children which can be a simple, acceptable, and effective way to remove plaque in children in order to improve their oral health in the absence of parental supervision.

Children accepted in the study will be randomly divided into two groups:

The traditional toothbrush group and the U-shaped toothbrush group, All children aged four to five years will have their plaque assessed with the Turesky Modified Quigley Hein Index (TMQH)

Detailed description: This study will evaluate the effectiveness U-shaped toothbrush in removing plaque and improving oral health. Children were randomly assigned to one of the following groups:

Group A: children in this group will use a traditional brush first to clean their teeth then will use U shaped brush later.

Group B: children in this group will use a U-shaped brush first to clean their teeth then will use a traditional brush later The plaque will be assessed by a blinded evaluator using the Turesky Modified Quigley Hein index (TMQH) in both groups at 4 different times(T0): before brush (T1): after brush (T2): a week after use (T3): a month of use The toothbrush will be changed after one month of use.

Eligibility criteria: Inclusion Criteria:

Medically free children. Complete temporary occlusion (no missing temporary teeth). The parents' approval for the child to enter the study.

Exclusion Criteria:

Children with limited ability to communicate. Children with motor disabilities.

Primary outcomes:
measure: Changing in plaque index
timeFrame: Plaque index will be measured before brushing (T0) and after brushing in both groups on the first day (T1), a week after use (T2), and after a month of use (T3) with each toothbrush
Secondary outcomes:
Other outcomes:
Locations:
city: Damascus
country: Syrian Arab Republic
facility: Damascus University
Study officials:
References:
Clinical trial NCT04456881: Arthroscopic Clinical Study of Double Bundle Anatomical Reconstruction of Medial Patellofemoral Ligament
Official title: Arthroscopic Clinical Study of Double Bundle Anatomical Reconstruction of Medial Patellofemoral Ligament
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Recurrent Patellar Dislocation
Keywords: arthroscopy
medial patellofemoral ligament
Lead sponsor: Peking University Third Hospital
Sponsor class: OTHER
First posted: 2020-07-07
Enrollment: 30
Sex: ALL
Minimum age (years): 17
Maximum age (years): 60
Standard ages: CHILD
ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: Objective: To study the clinical effect of double-beam anatomical reconstruction of medial patellofemoral ligament under arthroscopy.

Methods: Double-beam anatomical reconstruction of medial patellofemoral ligament was performed under arthroscopy in patients admitted to our hospital for treatment of recurrent patellar dislocation. Carry out preoperative and postoperative evaluations, and conduct preoperative and postoperative comparative studies to clarify the clinical effect of the procedure.

Expected results: Arthroscopic double-beam anatomical reconstruction of the medial patellofemoral ligament can effectively restore the stability of the patella and the motor function of the knee joint.

Expected conclusion: Arthroscopic double-beam anatomical reconstruction of the medial patellofemoral ligament is an effective minimally invasive technique.

Keywords: knee joint; medial patellofemoral ligament; double-beam anatomical reconstruction; arthroscopy


Eligibility criteria: Inclusion Criteria:

* 17\<age\<60 years
* Recurrent patellar dislocation or instability

Exclusion Criteria:

- Bone spurs or bone protrusions on the D-type of the femoral pulley or proximal of the pulley.

Primary outcomes:
measure: Lysholm score
timeFrame: 1 year after operation
measure: International Knee Documentation Committee (IKDC) 2000
timeFrame: 1 year after operation
measure: Tegner activity level score
timeFrame: 1 year after operation
Secondary outcomes:
Other outcomes:
Locations:
city: Beijing
country: China
facility: Institute of Sports Medicine, Peking University Third Hospital, Beijing Key Laboratory of Sports Injuries， Beijing, China
state: Beijing
Study officials:
References:
Clinical trial NCT00257881: Study Evaluating Intravenous CMD-193 in Subjects With Advanced Malignant Solid Tumors
Official title: Phase 1 Dose-Escalation Study of Intravenous CMD-193 in Subjects With Advanced Malignant Solid Tumors
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: PHASE1
Conditions: Neoplasms
Keywords: Tumor
Lead sponsor: Wyeth is now a wholly owned subsidiary of Pfizer
Sponsor class: INDUSTRY
First posted: 2005-11-23
Enrollment: 46
Sex: ALL
Minimum age (years): 20
Maximum age (years): 74
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: The primary purpose of this study is to evaluate the safety, tolerability, and maximum tolerated dose (MTD) of CMD-193 administered intravenously (IV) to subjects with advanced malignant tumors. The secondary purpose is to obtain preliminary information on the pharmacokinetics and antitumor activity of IV CMD-193.


Eligibility criteria: Inclusion Criteria:

* Malignant solid tumor progressed, or no standard treatment available
* Tumor expression of Lewis Y antigen

Exclusion Criteria:

* Cancer therapy within 28 days before enrollment
* Pregnant or breastfeeding women
* Unstable or serious concurrent medical conditions

Primary outcomes:
measure: Dose Limiting Toxicity, Adverse Event
Secondary outcomes:
measure: Pharmacokinetics parameters, Tumor assessment
Other outcomes:
Locations:
city: Tokyo
country: Japan
state: Chuo-ku
city: Nagaizumi-cho, Sunto-gun
country: Japan
state: Shizuoka
Study officials:
affiliation: Wyeth is now a wholly owned subsidiary of Pfizer
name: Medical Monitor
role: STUDY_DIRECTOR
References:
Clinical trial NCT01529281: Exercise-induced Muscle Damage is Reduced in Resistance Trained Athletes by Branch Chain Amino Acids
Official title: Exercise-induced Muscle Damage is Reduced in Resistance Trained Athletes by Branch Chain Amino Acids
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Exercise-induced Muscle Damage
Lead sponsor: Northumbria University
Sponsor class: OTHER
First posted: 2012-02-08
Enrollment: 12
Sex: MALE
Minimum age (years): 18
Maximum age (years): 30
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: It is well documented that exercise-induced muscle damage (EIMD) decreases muscle function and causes severe soreness and discomfort. Branched-chain amino acid (BCAA) supplementation has been shown to increase protein synthesis and decrease muscle protein breakdown, however, the effects of BCAAs on recovery from EIMD are unknown. Thus, the aim of this study was to examine the effects of a BCAA supplement on markers of muscle damage.


Eligibility criteria: Inclusion Criteria:

- Resistance trained males

Exclusion Criteria:

- Muscular skeletal disorders

Primary outcomes:
measure: Maximal voluntary contraction
timeFrame: pre exercise, 24 h, 48 h, 72 h, 96 h post-exercise
Secondary outcomes:
measure: Limb girths
timeFrame: pre-exercise, 24h, 48h, 72h, 96h
measure: Vertical jump
timeFrame: pre-exercise, 24h, 48h, 72h, 96h
measure: Creatine kinase
timeFrame: pre-exercise, 24h, 48h, 72h, 96h
measure: Muscle soreness
timeFrame: pre-exercise, 24h, 48h, 72h, 96h
Other outcomes:
Locations:
Study officials:
affiliation: Northumbria University
name: Glyn Howatson, PhD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Howatson G, Hoad M, Goodall S, Tallent J, Bell PG, French DN. Exercise-induced muscle damage is reduced in resistance-trained males by branched chain amino acids: a randomized, double-blind, placebo controlled study. J Int Soc Sports Nutr. 2012 Jul 12;9:20. doi: 10.1186/1550-2783-9-20. eCollection 2012.
Clinical trial NCT02869581: Institut Paoli-Calmettes Pancreatic Neoplasms Database
Official title: Institut Paoli-Calmettes Pancreatic Neoplasms Database
Study type: OBSERVATIONAL
Overall status: RECRUITING
Conditions: Pancreatic Neoplasms
Lead sponsor: Institut Paoli-Calmettes
Sponsor class: OTHER
First posted: 2016-08-17
Enrollment: 8500
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patient with a diagnosis of Pancreatic neoplasms

Brief summary: Database of Institut Paoli Calmettes diagnosed with Pancreatic neoplasms


Eligibility criteria: Inclusion Criteria:

* Patient with a diagnosis of Pancreatic neoplasm

Exclusion Criteria:

* Patient with a diagnosis of cholangiocarcinoma

Primary outcomes:
measure: Survival of patients with pancreatic neoplasms
timeFrame: 10 years
Secondary outcomes:
measure: Collection of patients characteristics
timeFrame: 10 years
Other outcomes:
Locations:
city: Marseille
country: France
facility: Institut Paoli Calmettes
state: Bouches du Rhone
Study officials:
References:
Clinical trial NCT06916910: Analysis of Predictive Factors for Urinary Leakage After Partial Nephrectomy for Renal Hilum Tumors
Official title: Analysis of Predictive Factors for Urinary Leakage After Partial Nephrectomy for Renal Hilum Tumors: A Multicenter Retrospective Clinical Study
Study type: OBSERVATIONAL
Overall status: ACTIVE_NOT_RECRUITING
Conditions: Partial Nephrectomy
Renal Hilum Tumors
Urinary Leakage
Keywords: urinary leakage
partial nephrectomy
renal hilum tumors
Lead sponsor: First Affiliated Hospital of Fujian Medical University
Sponsor class: OTHER
Collaborators: name: The Second Affiliated Hospital of Fujian Medical University
name: The First Affiliated Hospital of Xiamen University
First posted: 2025-04-08
Enrollment: 200
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients undergoing partial nephrectomy for renal hilum tumors

Brief summary: In this study, we plan to explore the risk factors closely related to the occurrence of urinary leakage after partial nephrectomy for renal hilum tumors through retrospective analysis of multicenter clinical data, thereby providing clinical guidance value for the prevention of postoperative urinary leakage.


Eligibility criteria: Inclusion Criteria:

* CT or MRI angiography indicates a renal hilum tumor, and the patient has undergone partial nephrectomy;
* The Eastern Cooperative Oncology Group (ECOG) performance status score is between 0 and 1, and the age is between 18 and 75 years old;
* The clinicopathological data are complete;
* There is no infection, autoimmune disease, hematological disease, or other malignancies.

Exclusion Criteria:

* The patient has surgical contraindications;
* There are congenital malformations of the urinary system, obstructive nephropathy, or other diseases that seriously affect the function of the urinary system before surgery;
* The patient has received relevant treatments that may affect the results of this study, such as radiotherapy in the kidney area, a history of kidney surgery, etc.;
* There are tumors in both kidneys.

Primary outcomes:
measure: Postoperative urinary leakage
timeFrame: the postoperative perirenal drainage volume being greater than 50 ml for 7 consecutive days and the creatinine level of the drainage fluid being similar to that of urine(μmol/L), or postoperative urinary leakage being suspected by imaging examination.
Secondary outcomes:
Other outcomes:
Locations:
city: Fuzhou
country: China
facility: first hospital affiliated of Fujian medical university
state: Fujian
Study officials:
References:
Clinical trial NCT00873210: Study In Patients With Kidney Cancer Treated With Sutent
Official title: Non-Interventional Study In Patients With Advanced And/Or Metastatic Renal Cell Carcinoma (mRCC) Treated With Sutent
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Advanced or Metastatic Renal Cell Carcinoma
Renal Cancer
Keywords: renal cell carcinoma
sunitinib malate
Lead sponsor: Pfizer
Sponsor class: INDUSTRY
First posted: 2009-04-01
Enrollment: 121
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Patients with advanced or metastatic renal cell carcinoma, that are indicated for 1st or 2nd line anticancer therapy.

Brief summary: Objective of this study is to increase knowledge about safety, tolerability, quality of life and efficacy under conditions of routine use of sunitinib.

Detailed description: Consecutive patients with advanced or metastatic renal cell carcinoma, that are indicated for 1st or 2nd line anticancer therapy

Eligibility criteria: Inclusion Criteria:

* Consecutive patients with advanced or metastatic renal cell carcinoma, that are indicated for 1st or 2nd line anticancer therapy

Exclusion Criteria:

* Hypersensitivity to sunitinib malate or to any of the excipients
* Any other contraindication to the use of sunitinib malate (based on decision of the treating physician).

Primary outcomes:
measure: Increased knowledge about safety, tolerability, quality of life and efficacy under conditions of routine use of sunitinib
timeFrame: 36 months
Secondary outcomes:
measure: Dose modifications
timeFrame: 36 months
measure: Incidence of new diagnosed hypertension
timeFrame: 36 months
measure: Incidence of new diagnosed hypothyroidism
timeFrame: 36 months
measure: Safety of sunitinib malate in "real-life" setting
timeFrame: 36 months
measure: Efficacy of sunitinib malate in "real-life" setting
timeFrame: 36 months
Other outcomes:
Locations:
city: Banska Bystrica
country: Slovakia
facility: Pfizer Investigational Site
city: Bojnice
country: Slovakia
facility: Pfizer Investigational Site
city: Bratislava
country: Slovakia
facility: Pfizer Investigational Site
city: Bratislava
country: Slovakia
facility: Pfizer Investigational Site
city: Kosice
country: Slovakia
facility: Pfizer Investigational Site
city: Michalovce
country: Slovakia
facility: Pfizer Investigational Site
city: Nitra
country: Slovakia
facility: Pfizer Investigational Site
city: Poprad
country: Slovakia
facility: Pfizer Investigational Site
city: Presov
country: Slovakia
facility: Pfizer Investigational Site
city: Ruzomberok
country: Slovakia
facility: Pfizer Investigational Site
city: Trebisov
country: Slovakia
facility: Pfizer Investigational Site
city: Trencin
country: Slovakia
facility: Pfizer Investigational Site
city: Trnava
country: Slovakia
facility: Pfizer Investigational Site
city: Zilina
country: Slovakia
facility: Pfizer Investigational Site
Study officials:
affiliation: Pfizer
name: Pfizer CT.gov Call Center
role: STUDY_DIRECTOR
References:
Clinical trial NCT00179010: AMP as a Better Delivery System of Adenosine
Official title: Use of AMP to Improve Tissue Delivery of Adenosine
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: PHASE1
Conditions: Ischemia
Keywords: Adenosine
AMP
Microdialysis
Blood Flow
Lead sponsor: Vanderbilt University Medical Center
Sponsor class: OTHER
First posted: 2005-09-15
Enrollment: 13
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: BASIC_SCIENCE

Brief summary: Adenosine and AMP are substances normally present in the body. Adenosine is also given for the treatment of some heart rhythm problems and may be used to reduce heart damage during heart attacks. The problem in using adenosine is that it is taken up by cells and, therefore, very little of the adenosine we give by vein or in the artery actually reaches the tissue. We propose to use AMP as a way to improve delivery of adenosine. AMP is inactive by itself, but is converted to adenosine in tissue. We hope that by giving AMP we will increase levels of adenosine in tissue. To see if this is true, we will give either adenosine or AMP into the forearm artery while we measure how much adenosine reaches the forearm tissue.


Eligibility criteria: Inclusion Criteria:

* Healthy volunteers
* Age 18-65
* Non smokers

Exclusion Criteria:

* Smokers
* Any chronic disease

Primary outcomes:
measure: Interstitial Adenosine Levels
timeFrame: Microdyalysis samples for adenosine, were collected for 15 minutes at each stage of the study (baseline and each dose of adenosine or AMP)
Secondary outcomes:
Other outcomes:
measure: Forearm Blood Flow
timeFrame: End of each stage (minute 15) of the study (baseline and each dose of adenosine or AMP ia infusions)
Locations:
city: Nashville
country: United States
facility: Vanderbilt University Medical Center
state: Tennessee
Study officials:
affiliation: Vanderbilt University
name: Italo Biaggioni, M.D.
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00988910: Effects of Drospirenone-containing or -Not Containing Combined Oral Contraceptives on General and Sexual Well-being
Official title: Observational Study on the Effects of DRSP-Containing Combined Oral Contraceptives (Yasmin,Yasminelle) and Other Combined Oral Contraceptives on the General and Sexual Well-Being in COC Users
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Contraception
Keywords: Combined Oral Contraceptives
COC
Lead sponsor: Bayer
Sponsor class: INDUSTRY
First posted: 2009-10-02
Enrollment: 632
Sex: FEMALE
Minimum age (years): 18
Maximum age (years): 45
Standard ages: ADULT
Accepts healthy volunteers: yes
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Healthy women using Combined Oral Contraceptive (COC)

Brief summary: The purpose of this study is to evaluate the symptoms and satisfaction for women taking drospirenone (DRSP)-containing combined oral contraceptives in comparison with women taking other kind of combined oral contraceptives.


Eligibility criteria: Inclusion Criteria:

* According to the label of the prescribed Combined Oral Contraceptive (COC)
* first Combined Oral Contraceptive use or previous Combined Oral Contraceptive use
* intention to use current COC for 1 year at least

Exclusion Criteria:

* Contraindications listed in the label of the prescribed Combined Oral Contraceptive (COC)

Primary outcomes:
measure: Psychophysical well-being evaluated by the Psychological General Well-Being Index (PGWBI)
timeFrame: at 12 months
measure: Sexual well-being evaluated by the Female Sexual Function Index (FSFI)
timeFrame: at 12 months
Secondary outcomes:
Other outcomes:
Locations:
city: Many Locations
country: Italy
Study officials:
affiliation: Bayer
name: Bayer Study Director
role: STUDY_DIRECTOR
References: